Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohn's Disease: Tipping the Balance

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

Crohn's disease (CD) is a chronic inflammatory disorder which may involve any part of gastrointestinal tract. Chronic inflammation is primarily due to an immunological imbalance between pro- and anti-inflammatory cytokines, and with a defective apoptosis of lamina propria T cells. Amongst the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) seems to play a central role in pathogenesis of CD.

Over the last years, increasing knowledge on the pathogenesis of CD together with progresses in bio-technology have led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, most importantly TNF-α and its receptors.

The aim of this paper is to critically review the rationale and state-of-the art for the use TNF-α inhibitors in the treatment of CD.

Keywords: Certolizumab pegol; Infliximab; Lipopolysaccaride; T lymphocytes; TNF receptors; Toll-like receptors

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986707780831104

Affiliations: Division of Gastroenterology,Istituto Clinico Humanitas-IRCCS in Gastroenterology, Viale Manzoni, Rozzano,Milan, Italy.

Publication date: June 1, 2007

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more